Access to all documents and request for further information are available to all users at no cost. In order to provide you with this free service, William Reed Business Media SAS does share your information with companies that have content on this site. When you access a document or request further information from this site, your information may be shared with the owners of that document or information.
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final product manufacture. It is the global leader in the production and support of chemical and biological active pharmaceutical ingredients. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts, which play an important role in the development of novel medicines and healthcare products. Lonza is also the world leader in microbial control providing innovative, chemistry-based and related solutions to destroy or to selectively inhibit the growth of harmful microorganisms. Its activities encompass the areas of water treatment, personal care, health and hygiene, industrial preservation, materials protection, and wood treatment. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition and agro markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange and secondary listed on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza is not subject to the SGX-ST’s continuing listing requirements. Lonza is subject to the listing rules of the SIX Swiss Exchange, which do not have specific requirements equivalent to the listing rules of the SGX-ST in respect of interested person transactions, acquisition and realizations, and delisting. In 2011, the company had sales of CHF 2.69 billion. Further information can be found at www.lonza.com .
For the nutrition market Lonza offers a portfolio of branded health ingredients:
Carnipure™ is high quality L-carnitine, a nutrient essential for energy metabolism. Extensive research shows that supplementary Carnipure™ can play a supportive role in many areas of health, including recovery from exercise, weight management and healthy aging.
Made from a proprietary strain of microalgae, DHAid™ is a purely vegetarian source of omega-3 DHA. Health benefits of DHAid™ include the support of brain development and function as well as heart and eye health.
ResistAid™ is a proprietary natural immune support ingredient that is formulated to deliver triple action immune benefits year round. Made from North American larch trees, it consists of arabinogalactan and bioactive flavonoids, and thus has antioxidant capacity.
The Memree™ brand covers a line of products that contain high quality, soy-based phosphatidylserine. Phosphatidylserine is an important structural component of cell membranes and is found in concentrated amounts in brain cells. Products in the Memree™ line include MemreePS™ for cognitive health applications and MemreePlus™ shown to reduce cortisol levels; cortisol is a hormone that is associated with stress, as well as impeded recovery after exercise.
Lonza is the leading supplier of vitamin B3 in the form of Niacin and Niacinamide. Vitamin B3 is an essential vitamin needed for protein, carbohydrate and fat metabolism. Niacin is also used to maintain healthy cholesterol levels. Vitamin B3 is widely used in food fortification, dietary supplements and pharmaceutical applications.